Weight Watchers launched The Weigh In, a podcast partnership with Dear Media, to directly address stigma surrounding GLP-1 weight-loss drugs, according to Glossy. The company is using long-form editorial content to reshape public perception of medications like Ozempic and Wegovy, steering the conversation away from celebrity gossip and toward clinical legitimacy. This is owned media deployed as reputation infrastructure.

The podcast features Samhita Mukhopadhyay, Weight Watchers' head of content and impact, and draws on Dear Media's distribution network to reach audiences already consuming wellness content. The format allows Weight Watchers to control messaging duration and depth in a way display ads and social posts cannot. Each episode runs long enough to unpack nuance, cite research, and preempt objections — editorial real estate the brand does not have to negotiate or pay per impression.

The mechanism here is message inoculation through owned narrative. When a category faces reputational headwinds — safety concerns, moral judgment, misinformation — brands that wait for media coverage to turn favorable cede the frame. Weight Watchers is instead producing the frame itself. By naming the stigma explicitly and dedicating recurring airtime to it, the company positions itself as the credible source on GLP-1 drugs, not a defendant in someone else's story. The audience builds trust through repeated exposure, and the content becomes referenceable: journalists, doctors, and consumers can point to the podcast as a counterweight to tabloid coverage.

This also solves a structural problem for physical-product brands in regulated or controversial categories. Paid advertising often restricts health claims. Influencer posts get flagged. Press coverage is unpredictable. A podcast is a first-party channel where the brand can speak at length, cite studies, interview clinicians, and address objections in the customer's own words — all without a media gatekeeper editing the message. Dear Media provides production quality and distribution scale, so the content does not sound like a corporate FAQ read aloud.

A small physical-product brand facing category stigma or confusion can run the same play on a constrained budget. First, identify the single most damaging misconception about your product — the one that stops the sale or triggers refunds. Write that misconception as a question. Launch a simple audio or video series, recorded on a phone, where you answer that question for 10 minutes once a week. Title the series after the question. Publish to YouTube, Spotify, and Apple Podcasts using a free host like Anchor. In the first episode, state the misconception, explain why it exists, then present your counter-evidence: customer results, third-party tests, or expert commentary. In subsequent episodes, interview customers who had the same fear and bought anyway, or bring on a subject-matter expert who can validate your position. Keep the format consistent so the series becomes a reference library. Link to specific episodes in email responses to objections, in product pages, and in customer service macros. The goal is not viral reach; it is to create a URL you control where the full counter-argument lives, so you never have to re-litigate the point in a Twitter thread or a one-paragraph FAQ.

The broader pattern: when your category has a reputation problem, owned content that directly names and refutes the problem outperforms cheerful brand storytelling. Stigma does not fade from silence. It fades from repeated, credible contradiction.